GlassScriptPhysician profile
Robert S Tillett, JR.
NPI 1134109465
$1,863.66
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,472 · 2020: $326 · 2021: $66.32.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $705.66 | 2019-2020 | |
| Emd Serono, INC. | $607.41 | 2019-2021 | |
| Allergan, INC. | $209.39 | 2019 | |
| Genentech, INC. | $63.68 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $58.45 | 2019-2021 | |
| Amgen INC. | $48.53 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $42.64 | 2019-2020 | |
| Genzyme Corporation | $41.38 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $35.70 | 2019 | |
| Grifols USA, LLC | $19.37 | 2019 | |
| Genentech USA, INC. | $17.12 | 2021 | |
| Boston Scientific Corporation | $14.33 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Tillett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.